{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:45:35Z","timestamp":1790358335877,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":335,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.ctarc.2020.100260","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T12:24:30Z","timestamp":1606911870000},"page":"100260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland"],"prefix":"10.1016","volume":"25","author":[{"given":"David","family":"Vizcaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette O.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kneip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korinna","family":"J\u00f6hrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Tukiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt A.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2020.100260_bib0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-3-34","article-title":"Malignant mesothelioma","volume":"3","author":"Moore","year":"2008","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ctarc.2020.100260_bib0002","first-page":"162","article-title":"Latency periods in asbestos-related mesothelioma of the pleura","volume":"6","author":"Bianchi","year":"1997","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.ctarc.2020.100260_bib0003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related diseases","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.ctarc.2020.100260_bib0004","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.ejca.2007.09.018","article-title":"Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register","volume":"43","author":"Marinaccio","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2020.100260_bib0005","unstructured":"GLOBOCAN. Cancer Today. Available at https:\/\/gco.iarc.fr\/today\/online-analysis-table."},{"key":"10.1016\/j.ctarc.2020.100260_bib0006","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11","author":"Ferlay J","year":"2013"},{"key":"10.1016\/j.ctarc.2020.100260_bib0007","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.ctarc.2020.100260_bib0008","article-title":"Estimation of country-specific mesothelioma deaths: a multivariate predictive model based on asbestos use","volume":"73","author":"Vizcaya","year":"2016","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.ctarc.2020.100260_bib0009","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.12688\/f1000research.15512.2","article-title":"Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort","volume":"7","author":"Amin","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ctarc.2020.100260_bib0010","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2018.08.007","article-title":"Survival by histologic subtype of malignant pleural mesothelioma and the impact of surgical resection on overall survival","volume":"19","author":"Verma","year":"2018","journal-title":"Clin. Lung. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100260_bib0011","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2559.2008.03178.x","article-title":"Problems in mesothelioma diagnosis","volume":"54","author":"Addis","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.ctarc.2020.100260_bib0013","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s004040100189","article-title":"The diagnostic challenge of peritoneal mesothelioma","volume":"266","author":"Krasuski","year":"2002","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ctarc.2020.100260_bib0014","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ctarc.2020.100260_bib0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2020.100260_bib0016","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0017","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0018","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2020.100260_bib0019","article-title":"Checkpoint inhibitor therapy after dendritic cell vaccination elicits tumor response in mesothelioma patients","author":"Cornelissen","year":"2019","journal-title":"AACR"},{"key":"10.1016\/j.ctarc.2020.100260_bib0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Creaney","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.ctarc.2020.100260_bib0021","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ctarc.2020.100260_bib0022","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0023","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/1471-2407-14-674","article-title":"A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice","volume":"14","author":"Linch","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2020.100260_bib0024","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2020.100260_bib0025","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma","volume":"28","author":"Wheatley-Price","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0026","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2020.100260_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctarc.2020.100260_bib0028","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","article-title":"Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study","volume":"43","author":"Valmary-Degano","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0029","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody Avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0031","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high pd-l1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2020.100260_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.03.001","article-title":"Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"96","author":"Cedres","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2020.100260_bib0033","doi-asserted-by":"crossref","first-page":"20769","DOI":"10.18632\/oncotarget.25100","article-title":"Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma","volume":"9","author":"Watanabe","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2020.100260_bib0034","doi-asserted-by":"crossref","first-page":"34103","DOI":"10.18632\/oncotarget.26135","article-title":"Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models","volume":"9","author":"Quanz","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2020.100260_bib0035","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0036","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/onc.2009.197","article-title":"Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors","volume":"28","author":"John","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2020.100260_bib0037","first-page":"34","article-title":"A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum\/pemetrexed-based chemotherapy (NCT02610140)","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"OA 02.01 Randomized Phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0039","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12254-016-0292-2","article-title":"PD-L1 testing, fit for routine evaluation? From a pathologist\u2019s point of view","volume":"9","author":"Hutarew","year":"2016","journal-title":"Memo"},{"key":"10.1016\/j.ctarc.2020.100260_bib0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2020.100260_bib0041","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jso.22024","article-title":"Mesothelin expression correlates with prolonged patient survival in gastric cancer","volume":"105","author":"Baba","year":"2012","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0042","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.ctarc.2020.100260_bib0043","doi-asserted-by":"crossref","first-page":"164","DOI":"10.9738\/INTSURG-D-13-00001.1","article-title":"Mesothelin expression is a prognostic factor in cholangiocellular carcinoma","volume":"98","author":"Nomura","year":"2013","journal-title":"Int. Surg."},{"key":"10.1016\/j.ctarc.2020.100260_bib0044","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2020.100260_bib0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/02841869409098430","article-title":"Data quality and quality control of a population-based cancer registry: experience in Finland","volume":"33","author":"Teppo","year":"1994","journal-title":"Acta Oncol. (Madr.)"},{"key":"10.1016\/j.ctarc.2020.100260_bib0046","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jtho.2020.08.004","article-title":"ID:2908 first-line nivolumab\u00a0+\u00a0ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: checkMate 743","volume":"15","author":"Baas","year":"2020","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2020.100260_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: translational evidence from two clinical trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:21:52Z","timestamp":1762842112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220300952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":47,"alternative-id":["S2468294220300952"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100260","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100260"}}